Plant Made Biopharmaceuticals NEXT-GENERATION THERAPEUTICS FOR ORPHAN DISEASES

Transcription

1 Plant Made Biopharmaceuticals NEXT-GENERATION THERAPEUTICS FOR ORPHAN DISEASES

2 BryoTechnology: enables delivery of a wide range of products customized according to the individual needs of our clients 02 03

3 PLANT MADE BIOPHARMACEUTICALS: OUR ASSET, YOUR ADVANTAGE We at Greenovation work to advance the development of new treatments that improve quality of life in patients suffering from rare genetic diseases. Greenovation is the inventor of BryoTechnology, a nextgeneration platform that exploits the unique advantages of the moss Physcomitrella patens for production of highly effective biopharmaceuticals. Today, Greenovation is a biopharmaceutical company specialized in development of moss made therapeutics, contract development and production as well as licensing and technology transfer.» Our vision is to provide moss made biopharmaceuticals that allow a safer and better treatment of patients suffering from orphan diseases.«dr. Thomas Frischmuth, CEO

4 BryoEngineering: rapid genome customization in moss for development of customized proteins GLYCOSYL TRANSFERASES TOXIN TARGETS PROTEASES DESIGNER GLYCOSYLATION TOXIN-RESISTANT PRODUCTION STRAINS PROTEASE-FREE PRODUCTION STRAINS 04 05

5 GET OPTIMIZED GLYCOSYLATION PATTERNS YOU NEED As moss is a higher eukaryote, it possesses the enzymatic machinery to carry out complex posttranslational modifications like glycosylations. These moss enzymes, including chaperones and glycosyltransferases are lined up along the secretory pathway, which is the standard route used for recombinant protein production by BryoTechnology. Moss N-glycans are free of core α-1,6 -fucose, which drastically increases the efficacy of IgG -products. This effect is due to increased CD16 -binding and has great potential for example in oncological applications. CUSTOMER SPECIFIC GENES CUSTOMER SPECIFIC Our BryoEngineering technology is straightforward: Precise and stable genome modifications can be introduced in Physcomitrella patens, this means that production strains express human N-glycosylation while non-human glycosylation with immunogenic potential is prevented. The haplontic organism with its high rate of homologous recombination along with knowledge of the fully sequenced genome, allows for precise editing of any moss gene. The customized platforms mean that specific proteins can be produced quickly. The technology allows adaptations such as protease knockouts or toxin-resistant ADC-production platforms.

6 06 07

7 Greenovation offers the full range from transient, small scale production to process development of biopharmaceutical production in GMP-compliant, several hundred litre wave bioreactors.

8 Key attributes of BryoTechnology: outstanding product quality with posttranslational modifications batch-to-batch stability excellent safety profile virus and TSE-free production in customizable strains 08 09

9 SCALABLE PRODUCTION OF HIGHLY EFFECTIVE BIOPHARMACEUTICALS Exploiting the unique advantages of the moss Physcomitrella patens, BryoTechnology is a next-generation manufacturing technology for production of a wide range of biopharmaceuticals. Greenovation s moss-based technologies BryoSpeed and BryoMaster include a wide range of advantages for biopharmaceutical development and production processes. Greenovation offers the full range from transient, small scale production to process development of biopharmaceutical production in GMP-compliant, several hundred litre wave bioreactors. BryoMaster We offer the development of stable production strains cultivated in a photoautotrophic fermentation process for production of large scale batches. BryoSpeed We offer rapid delivery of initial, high quality product samples, based on transiently transfected protoplasts. Repeated harvesting yields µg to mg amounts of high-quality, fully glycosylated product. Regulatory compliance We have created a cgmp-compliant production process comparable to established production strategies. Moss -based biopharmaceutical production is safe and allows for straightforward technology transfer and scale adaption.

10 TAKE ADVANTAGE OF OUR TECHNOLOGY AND KNOWLEDGE Proprietary Drug Candidates Our development pipeline includes proprietary drug candidates for orphan diseases like Fabry Disease, Gaucher's Disease, the atypical hemolytic uremic syndrome and Pompe Disease. Our lead candidates moss-agal and moss-gba are substitutes for human lysosomal enzymes, developed for enzyme replacement therapy (ERT), which compensates for a genetically-determined lack of an enzyme by regular infusion of a biotechnologically-produced substitute. Contract Development & Production Greenovation offers the full range of contract development and manufacturing from transient protein productions to customized drug substances and drug products using stable cell lines. This allows our clients not only to test desired protein products quickly, but also to access contract manufactured biopharmaceuticals for clinical studies and market supply. Technology Transfer Our moss-based technologies and IP portfolio cover plant production processes, N-glycosylation techniques and mechanisms-of-action. This has a wide range of advantages for biopharmaceutical development and production processes. We offer clients access to our BryoTechnology platform and broad IP portfolio via a wide range of licensing models. Alternatively, you can directly benefit from the know-how and experience of our team at your production site

11

12 Visit us at www. greenovation. com